Open AccessVitamin Drug conjugate: a systematic review of pharmacological potential
Author(s) -
Ritesh P. Bhole,
Yogita Shinde,
Chandrakant Bonde,
Ravindra D. Wavhale
Publication year - 2021
Publication title -
ķaraġandy universitetìnìn̦ habaršysy. himiâ seriâsy
Language(s) - English
Resource type - Journals
eISSN - 2663-4872
pISSN - 2518-718X
DOI - 10.31489/2021ch1/27-52
Subject(s) - tuberculosis , medicine , drug , drug resistance , pharmacology , disease , population , biology , pathology , microbiology and biotechnology , environmental health
Cancer is a chronic disease which can cause death. In traditional chemotherapycytotoxic drugs are used to kill proliferating cancer cells. The cytotoxic agent exhibits less specificity, less biological activity, causes sys-temic toxicity and undesirable side effects. Each year, about 1.8 million of the population are infected and die due to tuberculosis infection. An increase of drug resistance during the tuberculosis treatment is a significant concern. So, it is necessary to develop a new approach or therapies to resolve drug resistance, drug selectivity in tuberculosis infection and the reduction of the side effects of cytotoxic agents and anti-tubercular drugs. This review describes the newly emerging concept of «vitamin drug conjugate». Vitamin-drug conjugate is a specifically carried drug toward the target site, is one of the promising ways to treat chronic diseases like can-cer and tuberculosis and enhance the therapeutic outcome. The purpose of this review is to explore vitamin as a targeting moiety for new anticancer and anti-tubercular drug to overcome challenges, such as non-selectivity, systemic toxicity and multidrug resistance. This approach is beneficial in the treatment of life-threatening disease like cancer, tuberculosis and also in many viral infections.